ATLANTA, July 11, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that 8 presentations on ILUVIEN data have been accepted during the 36th Annual Meeting of the American Society of Retina Specialists (ASRS) in Vancouver, BC, Canada, July 20 through 25th.
"We are pleased with our podium presence this year at ASRS," said Dan Myers, CEO of Alimera. "The data will reflect the benefit of ILUVIEN's CONTINUOUS MICRODOSING in treating DME including a reduction in the recurrence of the disease, a reduced number of injections compared to what DME patients normally endure, and potential quality of life improvements. There will also be additional data reinforcing the predictability of an intraocular pressure rise with the use of ILUVIEN."
The podium presentations are scheduled at the following dates and times:
Tuesday, July 24, 2018, from 9:00 a.m. to 9:35 a.m.
- Reduction in the Frequency of Diabetic Macular Edema (DME) Therapies Post-0.2 µg/Day Fluocinolone Acetonide (FAc) Implant Treatment Results, Sam Mansour, MD, MSc, FACS, FRCS(C)
- 2 Real-World Analyses of Treatment Burden Associated with Intravitreal Injections for DME Prior to 0.2 µg/Day Fluocinolone Acetonide (FAc), Nancy Holekamp, MD
Tuesday, July 24, 2018, from 11:00 a.m. to 12:00 p.m.
- Effect on Treatment Burden Post-Versus Pre-ILUVIEN Based on Prior DME Treatments, Caesar Luo, MD
- Best Corrected Visual Acuity (BCVA) and Central Macular Thickness (MAT) Outcomes After Fluocinolone Acetonide Intravitreal Implant Injection, Dana Deupree, MD
Tuesday, July 24, 2018, from 1:20 a.m. to 2:00 p.m.
- The Translation of CST to Visual Function: Persistent DME and QOL Measures with FAc Implants in the FAME Study, Michael Singer, MD
The following posters and posters on demand will also be available at the meeting:
- Choosing the Optimal Corticosteroid to Treat Diabetic Macular Edema (DME) Prior to Using 0.2 ug/day Fluocinolone Acetonide Implant (FAc; ILUVIEN), Joshua Mali, MD
Posters on Demand
- Effect of Fluocinolone Acetonide (FAc) 0.2µg/day (ILUVIEN) Implant on the Decision to Drive in Patients with Differential Control of DME, Seenu M. Hariprasad, MD, Chicago, IL; Dilraj S. Grewal, MD, Durham, NC
- Prior Steroid Response as a Predictor of Real-World IOP Safety with 0.2 μg/day Fluocinolone Acetonide (FAc) in Diabetic Macular Edema (DME) Therapy (PALADIN & USER), Jay Prensky, MD
ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is a sustained release intravitreal implant approved in the U.S. to treat diabetic macular edema in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. Each ILUVIEN implant is designed to release submicrogram levels of fluocinolone acetonide, a corticosteroid, for up to 36 months.
About Diabetic Macular Edema (DME)
DME, the primary cause of vision loss associated with diabetic retinopathy, is a disease affecting the macula, the part of the retina responsible for central vision. When the blood vessel leakage associated with diabetic retinopathy results in swelling of the macula, the condition is called DME. The onset of DME is painless and may go unreported by the patient until it manifests with the blurring of central vision or acute vision loss. The severity of this blurring may range from mild to profound loss of vision. The Wisconsin Epidemiologic Study of Diabetic Retinopathy found that over a 10-year period approximately 19% of people with diabetes included in the study were diagnosed with DME. All people with type 1 or type 2 diabetes are at risk of developing DME. As the population of people with diabetes increases, Alimera expects the annual incidence of diagnosed DME to increase, as well.
About Alimera Sciences, Inc.
Alimera, founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera's commitment to retina specialists and their patients is manifest in Alimera's product and development portfolio designed to treat early- and late-stage diseases. For more information, please visit www.alimerasciences.com.
SOURCE Alimera Sciences, Inc.